nach oben

Erschienen in:

24.02.2016 | Hypotonie | zertifizierte fortbildung

Abrupter Blutdruckabfall

Evidenzbasierte Therapie der neurogenen orthostatischen Hypotonie

verfasst von: Dr. med. univ. Sabine Eschlböck, Dr. med. univ. Alessandra Fanciulli, PhD, Univ. Prof. Dr. med. univ. Gregor Wenning, PhD

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine orthostatische Hypotension, die im Rahmen von neurologischen Erkrankungen auftreten kann und mit einem kardiovaskulären Versagen vergesellschaftet ist, führt zu einer erheblichen Beeinträchtigung der Lebensqualität des Patienten. Ein adäquates Management ist daher von besonderer Relevanz.

Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich). 2013;15(3):147–53.CrossRef

Low P, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7(5):451–8.PubMedCentralCrossRefPubMed

Kaufmann H. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. 1996;6(2):125–6.CrossRefPubMed

Wasner G, Baron R. Orthostatische Kreislaufdysregulation - Klinik, Pathophysiologie und Therapie Orthostatische Kreislaufdysregulation - Klinik, Pathophysiologie und Therapie. Akt Neurol. 2000;27(4):157–69.CrossRef

Asahina M, Vichayanrat E, Low DA, et al. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2013;84(6):674–80.CrossRefPubMed

Schroeder C, Jordan J, Kaufmann H. Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs. 2013;73(12):1267–79.CrossRefPubMed

Herold G, Mitarbeiter. Innere Medizin 2012. Gerd Herold Verlag 2011. ISBN: 978-3-9814660-1-0

Chobanian A, Bakris G, Black H, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.CrossRefPubMed

Fanciulli A, Strano S, Colosimo C, et al. The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies. Eur J Neurol. 2013;20(2):231–5.CrossRefPubMed

10.

Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41(5):587–94.CrossRefPubMed

11.

Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161(1-2):46–8.CrossRefPubMed

12.

Ha A, Brown C, York M, et al. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Park Relat Disord. 2011;17(8):625–8.CrossRef

13.

Velseboer DC, de Haan RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Park Relat Disord. 2011;17(10):724–9.CrossRef

14.

Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139–46.PubMedCentralCrossRefPubMed

15.

Metzler M, Duerr S, Granata R, et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212–9.PubMedCentralCrossRefPubMed

16.

Low P. Prevalence of orthostatic hypotension. Clin Aut Res. 2008;18(Suppl 1):8–13.CrossRef

17.

Asahina M, Young TM, Bleasdale-Barr K, et al. Differences in overshoot of blood pressure after head-up tilt in two groups with chronic autonomic failure: pure autonomic failure and multiple system atrophy. J Neurol. 2005;252(1):72–7.CrossRefPubMed

18.

Schmidt C, Berg D, Herting, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24(14):2136–42.CrossRefPubMed

19.

Jordan J, Shannon J, Diedrich A, et al. Water potentiates the pressor effect of ephedra alkaloids. Circulation. 2004;109(15):1823–5.CrossRefPubMed

20.

Wieling W, Van Lieshout J, Hainsworth R. Extracellular fluid volume expansion in patients with posturally related syncope. Clin Aut Res. 2002;12(4):242–9.CrossRef

21.

Shannon J, Diedrich A, Biaggioni I, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med. 2002;112(15):355–60.CrossRefPubMed

22.

Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Aut Res. 2008;18(Suppl 1):14–8.CrossRef

23.

El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart. 1996;75(2):134–40.PubMedCentralCrossRefPubMed

24.

Diedrich A, Biaggioni I. Segmental orthostatic fluid shifts. Clin Aut Res. 2004;14(3):146-7.

25.

Smit A, Wieling W, Fujimura J, et al. Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Aut Res. 2004;14(3):167–75.

26.

Denq J, Opfer-Gehrking T, Giuliani M, et al. Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin Aut Res. 1997;7(6):321–6.CrossRef

27.

Podoleanu C, Maggi R, Brignole M, et al. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol. 2006;48(7):1425–32.CrossRefPubMed

28.

Jordan J, Shannon J, Grogan E, et al. A potent pressor response elicited by drinking water. Lancet. 1999;353(9154):723.CrossRefPubMed

29.

Wieling W, van Lieshout J, van Leeuwen A. Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin Aut Res. 1993;3(1):57–65.CrossRef

30.

Ten Harkel A, van Lieshout J, Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin Sci (Lond). 1994;87(5):553–8.CrossRef

31.

Van Lieshout J, ten Harkel A, Wieling W. Physical manoeuvres for combating orthostatic dizziness in autonomic failure. Lancet. 1992;339(8798):897–8.CrossRefPubMed

32.

Tutaj M, Marthol H, Berlin D, et al. Effect of physical countermaneuvers on orthostatic hypotension in familial dysautonomia. J Neurol. 2006;253(1):65–72.CrossRefPubMed

33.

Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol. 2002;9(3):195–9.CrossRefPubMed

34.

Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Hear J. 2009;30(21):2631–71.CrossRef

35.

Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. J Neural Transm. 2005;112(12):1695–704.CrossRefPubMed

36.

Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord. 2005;20(Suppl 1):S67–76.CrossRefPubMed

37.

Brainin M, Barnes M, Baron J, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. Eur J Neurol. 2004;11(9):577–81.CrossRefPubMed

38.

Wenning GK, Braune S. Multiple system atrophy: pathophysiology and management. CNS Drugs. 2001;15(11):839–52.CrossRefPubMed

39.

Low P, Gilden J, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–51.CrossRefPubMed

40.

Wright R, Kaufmann H, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–4.CrossRefPubMed

41.

Jankovic J, Gilden J, Hiner B, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.CrossRefPubMed

42.

Sanchez-Ferro A, Benito-Leon J, Gomez-Esteban JC. The management of orthostatic hypotension in Parkinson’s disease. Front Neurol. 2013;4:64.PubMedCentralCrossRefPubMed

43.

Lullmann H, Mohr K, Hein L. Pharmakologie und Toxikologie. Georg-Thieme Verlag 2006; 16.Auflage. ISBN:978-3-13-368516-0

44.

Vilches-Moraga A, Paling D, Akram Q, et al. Midodrine hydrochloride in the management of older adults with neurocardiogenic syncope and orthostatic hypotension: A prospective observational study. Eur Geriatr Med. 2012;3(5):295–8.CrossRef

45.

Izcovich A, Gonzalez Malla C, Manzotti M, et al. Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review. Neurology. 2014;83(13):1170–7.CrossRefPubMed

46.

Parsaik AK, Singh B, Altayar O, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013;28(11):1496–503.PubMedCentralCrossRefPubMed

47.

Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–6.CrossRefPubMed

48.

Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol. 2009;256(11):1791–808.CrossRefPubMed

49.

Fouad-Tarazi F, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604–10.CrossRefPubMed

50.

Goldstein DS, Pechnik S, Holmes C, et al. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003;42(2):136–42.CrossRefPubMed

51.

Beubler E. Kompendium der Pharmakologie. Gebrauchliche Arzneimittel in der Praxis. Springer Verlag 2011; 3. Auflage. ISBN:978-3-7091-0659-4

52.

Campbell I, Ewing D, Clarke B. 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes. 1975;24(4):381–4.CrossRefPubMed

53.

Hoehn M. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch Neurol. 1975;32(1):50–1.CrossRefPubMed

54.

Schoffer KL, Henderson RD, O'Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007;22(11):1543–9.CrossRefPubMed

55.

Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615–24.CrossRefPubMed

56.

Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53(9):2151–7.CrossRefPubMed

57.

Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–8.CrossRefPubMed

58.

Mathias C, Senard J, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res. 2001;11(4):235–42.CrossRef

59.

Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis. 2014;4(1):57–65.PubMed

60.

Kaufmann H, Freeman R, Biaggioni, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial Neurology. 2014. 83(4):328–35.PubMed

61.

Akizawa T, Koshikawa S, Iida N, et al. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Nephron. 2002;90(4):384–90.CrossRefPubMed

62.

Iida N, Koshikawa S, Akizawa T, et al. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Am J Nephrol. 2002;22(4):338-46.

63.

Biaggioni I, Freeman R, Mathias CJ, et al. Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa. Hypertension. 2015;65(1):101–7.PubMedCentralCrossRefPubMed

64.

Traynor K. Droxidopa approved for neurogenic orthostatic hypotension. Am J Health Syst Pharm. 2014;71(7):520.

65.

Deguchi K, Ikeda K, Sasaki I, et al. Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy. J Neurol. 2007;254(6):735–40.CrossRefPubMed

66.

Humm A, Mason L, Mathias C. Effects of water drinking on cardiovascular responses to supine exercise and on orthostatic hypotension after exercise in pure autonomic failure. J Neurol Neurosurg Psychiatry. 2008;79(10):1160–4.CrossRefPubMed

67.

Lipsitz L, Ryan S, Parker J, et al. Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. Circulation. 1993;87(2):391–400.CrossRef

68.

Bordet R, Benhadjali J, Destee A, et al. Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration. Clin Neuropharmacol. 1995;18(1):83–9.CrossRefPubMed

69.

Alam M, Smith G, Bleasdale-Barr K, et al. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens. 1995;13(12 Pt 2):1664–9.PubMed

70.

Bordet R, Benhadjali J, Libersa C, et al. Octreotide in the management of orthostatic hypotension in multiple system atrophy: pilot trial of chronic administration. Clin Neuropharmacol. 1994;17(4):380–3.CrossRefPubMed

71.

Hoeldtke R, Horvath G, Bryner K, et al. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab. 1998;83(2):339–43.PubMed

72.

Fanciulli A, Wenning G. Multiple-system atrophy. N Engl J Med. 2015;372(3):249–63.CrossRefPubMed

73.

Onrot J, Goldberg M, Biaggioni I, et al. Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med. 1985;313(9):549–54.CrossRefPubMed

74.

Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension. 2007;50(1):54–61.CrossRefPubMed

75.

Fukushima T, Asahina M, Fujinuma Y, et al. Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy. J Neurol. 2013;260(2):475–83.CrossRefPubMed

76.

Friedrich C, Reichmann H, Ziemssen T. Treatment of autonomic dysfunction in patients with extrapyramidal disorders. Fortschr Neurol Psychiatr. 2010;78(8):445–55.CrossRefPubMed

77.

Shibao C, Gamboa A, Diedrich A, et al. Management of hypertension in the setting of autonomic dysfunction. Curr Treat Options Cardiovasc Med. 2006;8(2):105–9.CrossRefPubMed

78.

Jordan J, Shannon J, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10(1):35–42.PubMed

79.

Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30(5):1062–7.CrossRefPubMed

80.

Shibao C, Gamboa A, Abraham R, et al. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006;47(3):522–6.CrossRefPubMed

81.

Mazza A, Ravenni R, Antonini A, et al. Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. Neurol Sci. 2013;34(5):621–7.CrossRefPubMed

82.

Arnold A, Okamoto L, Gamboa A, et al. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013;61(3):701–6.

83.

Ong AC, Myint PK, Shepstone L, et al. A systematic review of the pharmacological management of orthostatic hypotension. Int J Clin Pract. 2013;67(7):633–46.CrossRefPubMed

Titel: Abrupter Blutdruckabfall
Evidenzbasierte Therapie der neurogenen orthostatischen Hypotonie
verfasst von: Dr. med. univ. Sabine Eschlböck
Dr. med. univ. Alessandra Fanciulli, PhD
Univ. Prof. Dr. med. univ. Gregor Wenning, PhD
Publikationsdatum: 24.02.2016
Verlag: Springer Medizin
Schlagwörter: Hypotonie
Hypotonie
Hypertonie
Hypertonie
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 2/2016
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-016-1585-z

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Sind Opioide wirksam?

Neue Option bei Glioblastom

Ein pathogenetischer Faktor

Imageproblem: Locked-in im Wachkoma

Neue Darreichungsform

Wachstumsdifferenzierungsfaktor 15 ist ein hoch spezifischer Biomarker